175 related articles for article (PubMed ID: 37105059)
1. Direct oral anticoagulant (DOACs) prescribing practices of members of the Society of Gynecologic Oncology and American Society of Clinical Oncology.
Scanlon LR; Khaksari B; Goel S; Nevadunsky NS; Wright JD; Gressel GM
Gynecol Oncol; 2023 Jun; 173():68-73. PubMed ID: 37105059
[TBL] [Abstract][Full Text] [Related]
2. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
[TBL] [Abstract][Full Text] [Related]
3. Direct oral anticoagulant use in gynecologic oncology: A Society of Gynecologic Oncology Clinical Practice Statement.
Gressel GM; Marcus JZ; Mullen MM; Sinno AK
Gynecol Oncol; 2021 Jan; 160(1):312-321. PubMed ID: 33257014
[TBL] [Abstract][Full Text] [Related]
4. Safety of direct oral anticoagulants versus traditional anticoagulants in venous thromboembolism.
Giustozzi M; Franco L; Vedovati MC; Becattini C; Agnelli G
J Thromb Thrombolysis; 2019 Oct; 48(3):439-453. PubMed ID: 31104194
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism prophylaxis for laparoscopic surgery: a survey of members of the Society of Gynecologic Oncology.
Worley MJ; Rauh-Hain JA; Sandberg EM; Muto MG
Int J Gynecol Cancer; 2013 Jan; 23(1):208-15. PubMed ID: 23221603
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis.
Lyman GH; Kuderer NM
Thromb Res; 2020 Jul; 191 Suppl 1():S79-S84. PubMed ID: 32736784
[TBL] [Abstract][Full Text] [Related]
8. Management of venous thromboembolism in cancer patients: Considerations about the clinical practice guideline update of the American society of clinical oncology.
Verso M; Di Nisio M
Eur J Intern Med; 2020 Jan; 71():4-7. PubMed ID: 31732452
[TBL] [Abstract][Full Text] [Related]
9. Treatment of venous thromboembolism in patients with cancer: from clinical trials to real life.
Verso M; Agnelli G
Thromb Res; 2020 Jul; 191 Suppl 1():S123-S127. PubMed ID: 32736770
[TBL] [Abstract][Full Text] [Related]
10. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
Vedovati MC; Giustozzi M; Becattini C
Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
Ross JA; Miller MM; Rojas Hernandez CM
Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
[TBL] [Abstract][Full Text] [Related]
12. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.
Key NS; Khorana AA; Kuderer NM; Bohlke K; Lee AYY; Arcelus JI; Wong SL; Balaban EP; Flowers CR; Francis CW; Gates LE; Kakkar AK; Levine MN; Liebman HA; Tempero MA; Lyman GH; Falanga A
J Clin Oncol; 2020 Feb; 38(5):496-520. PubMed ID: 31381464
[TBL] [Abstract][Full Text] [Related]
13. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants.
Posch F; Königsbrügge O; Zielinski C; Pabinger I; Ay C
Thromb Res; 2015 Sep; 136(3):582-9. PubMed ID: 26210891
[TBL] [Abstract][Full Text] [Related]
14. Prescribing pattern of anticoagulants in patients with cancer associated thrombosis: Results of a survey among MITO group and AIOM society.
Milani A; Tuninetti V; Pignata S; Lorusso D; Castaldo D; De Giorgi U; Savarese A; Biglia N; Scandurra G; Mangili G; Di Maio M; Turinetto M; Bellero M; Mammoliti S; Testa S; Scotto G; Purro A; Artioli G; Valabrega G
Tumori; 2023 Oct; 109(5):490-495. PubMed ID: 36609207
[TBL] [Abstract][Full Text] [Related]
15. First-Line Therapies for VTE Treatment and Secondary Prophylaxis in Patients With Cancer: A New Direction.
Vogel SM; Smith LV; Peterson EJ
J Pharm Pract; 2020 Jun; 33(3):356-363. PubMed ID: 30541367
[TBL] [Abstract][Full Text] [Related]
16. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
17. Prophylaxis of thromboembolism during therapy with asparaginase in adults with acute lymphoblastic leukaemia.
Rank CU; Lynggaard LS; Als-Nielsen B; Stock W; Toft N; Nielsen OJ; Frandsen TL; Tuckuviene R; Schmiegelow K
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD013399. PubMed ID: 33038027
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Direct Oral Anticoagulant Therapy in Patients With Cancer.
Fovel LM; Seabury RW; Miller CD; Darko W; Probst LA; Horvath L
J Pharm Pract; 2021 Oct; 34(5):710-714. PubMed ID: 31888399
[TBL] [Abstract][Full Text] [Related]
19. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
Pernod G; Joly M; Sonnet B
J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
[TBL] [Abstract][Full Text] [Related]
20. The effectiveness and safety of direct oral anticoagulants compared to conventional pharmacologic thromboprophylaxis in hip fracture patients: A systematic review and meta-analysis of randomized controlled trials.
Abatzis-Papadopoulos M; Tigkiropoulos K; Nikas S; Papoutsis I; Kostopoulou O; Stavridis K; Karamanos D; Lazaridis I; Saratzis N
Orthop Traumatol Surg Res; 2023 Apr; 109(2):103364. PubMed ID: 35817368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]